secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001193125-22-274491
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Johnson & Johnson to acquire Abiomed for $380/share plus CVR; enterprise value ~$16.6B
--------------------------------------------------------------------------------

- Upfront cash $380/share + CVR up to $35/share; total implied value ~$415/share.
- Enterprise value ~$16.6B including cash acquired; deal expected to close by mid-2023.
- CVR milestones: net sales >$3.7B; FDA approval for Impella in STEMI; Class I guidelines.
- Transaction broadens JNJ MedTech cardiovascular portfolio; accretive to adjusted EPS in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/0001193125-22-274491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/d395813d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-274491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer